These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18400122)

  • 1. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
    Mühlberger N; Sroczynski G; Esteban E; Mittendorf T; Miksad RA; Siebert U
    Int J Technol Assess Health Care; 2008; 24(2):184-92. PubMed ID: 18400122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
    Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
    Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluation of Cervical Cancer Screening by HPV DNA, VIA, and Pap smear Methods in Indonesia.
    Hafidz F; Icanervilia AV; Rizal MF; Listiani P; Setyaningsih H; Sasanti ML; Ekawati FM; Atthobari JA; Utami TW; Trirahmanto A; Tjokroprawiro BA; Harsono AB; Masytoh LS; Haryani W; Subekti Y; Nadjib M
    Asian Pac J Cancer Prev; 2024 Sep; 25(9):3015-3022. PubMed ID: 39342578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
    Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
    Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.
    Kulasingam SL; Rajan R; St Pierre Y; Atwood CV; Myers ER; Franco EL
    BMC Med; 2009 Nov; 7():69. PubMed ID: 19900264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of screening and treatment of cervical dyskaryosis in Germany.
    Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
    Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
    Petry KU; Barth C; Wasem J; Neumann A
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
    Barré S; Massetti M; Leleu H; De Bels F
    BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
    Ezat SW; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
    Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
    Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
    Holmes J; Hemmett L; Garfield S
    Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
    Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
    BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology.
    Cochand-Priollet B; Le Galès C; de Cremoux P; Molinié V; Sastre-Garau X; Vacher-Lavenu MC; Vielh P; Coste J;
    Diagn Cytopathol; 2001 Jun; 24(6):412-20. PubMed ID: 11391824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.